menu

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

    Released May 22, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

    Released May 22, 2017

Facebook Comments

Schedule2 Jul 2022
Webpack App